# A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT00937352** · PHASE3 · TERMINATED · sponsor: **JANSSEN Alzheimer Immunotherapy Research & Development, LLC** · enrollment: 896 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Bapineuzumab

## Key facts

- **NCT ID:** NCT00937352
- **Lead sponsor:** JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 896 (ACTUAL)
- **Last updated:** 2013-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937352, "A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00937352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*